Table 2.
Adverse event, n (%) | Pre-IFX patients (n = 908) | Non-IFX patients (n = 6,191) | Total (n = 7,099) | P value |
---|---|---|---|---|
Any adverse event | 265 (29.2) | 2,159 (34.9) | 2,424 (34.1) | <0.001 |
Serious adverse events | 42 (4.6) | 500 (8.1) | 542 (7.6) | <0.001 |
Death | 2 (0.2) | 31 (0.5) | 33 (0.5) | ns |
Malignancy | 1 (0.1) | 17 (0.3) | 18 (0.3) | ns |
Serious infection | 23 (2.5) | 202 (3.3) | 225 (3.2) | ns |
Non-serious infection | 55 (6.1)) | 473 (7.6) | 528 (7.4) | ns |
IFX infliximab; ns not significant